<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564057</url>
  </required_header>
  <id_info>
    <org_study_id>44758</org_study_id>
    <nct_id>NCT00564057</nct_id>
  </id_info>
  <brief_title>Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine</brief_title>
  <official_title>Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are
      associated with an increased risk of cardiovascular disease: a wide range of alterations in
      lipid and glucose metabolism has been increasingly recognized in HIV patients treated with
      HAART. Few data are available on the effects of antihypertensive treatment on cardiac
      morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study
      is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or
      calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV
      hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morpho-functional left ventricle characteristics</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolic profile</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>systolic and diastolic blood pressure</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>candesartan 8-16 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lercanidipine 10-20 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan</intervention_name>
    <description>tablet 8-16 mg once daily, one year</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lercanidipine</intervention_name>
    <description>tablets 10-20 mg once daily, one year</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  office blood pressure &gt; 140/90 mmHg

          -  no antihypertensive treatment

          -  good quality echocardiogram

        Exclusion Criteria:

          -  cardiovascular diseases

          -  hypothyroidism

          -  diabetes

          -  secondary hypertension

          -  hepatic and renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>anna maria grandi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Insubria, Varese, ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>paolo grossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Insubria, Varese, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>andrea maria maresca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Insubria, Varese, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>eleonora nicolini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Insubria, Varese, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>massimo giola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Insubria, Varese, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>anna maria grandi, MD</last_name>
    <phone>+39 0332 278403</phone>
    <email>amgrandi@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Insubria, Department of Clinical Medicine</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med. 2005 Apr;118 Suppl 2:23S-28S. Review.</citation>
    <PMID>15903292</PMID>
  </reference>
  <reference>
    <citation>Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003 Jul;21(7):1377-82.</citation>
    <PMID>12817187</PMID>
  </reference>
  <reference>
    <citation>Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 Nov 20;349(21):1993-2003. Erratum in: N Engl J Med. 2004 Feb 26;350(9):955.</citation>
    <PMID>14627784</PMID>
  </reference>
  <reference>
    <citation>Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee S, Nelson KE, Tong W, Lai S. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):306-10.</citation>
    <PMID>12131567</PMID>
  </reference>
  <reference>
    <citation>Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003 Aug;21(8):1563-74.</citation>
    <PMID>12872052</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>December 5, 2007</last_update_submitted>
  <last_update_submitted_qc>December 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>blood pressure</keyword>
  <keyword>left ventricle</keyword>
  <keyword>metabolic profile</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Lercanidipine</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

